Boston Scientific touts CMS reimbursement nod for asthma treatment | Regulatory Roundup

January 4, 2012 by MassDevice staff

Boston Scientific's Alair bronchial thermoplasty system won pass-through payment approval from the Centers for Medicare & Medicaid Services.


Boston Scientific Corp.'s (NYSE:BSX) Alair asthma management system won reimbursement from the Centers for Medicare & Medicaid Services, effective at the start of this year.

The Alair system delivers precise thermal energy lung to tissue via bronchoscope to reduce excessively smooth muscle, decreasing the airway's ability to constrict.

The federal agency granted the Alair device approval for Medicare reimbursement through a separate "pass-through" payment when the procedure is performed in outpatient settings, the Natick, Mass.-based med-tech titan announced.

Sign up to get our free newsletters delivered right to your inbox

The approval allows hospitals to receive payment for the Alair catheter in addition to Medicare payment for the bronchial thermoplasty procedure, according to a press release.

"CMS' decision that the Alair bronchial thermoplasty system meets the criteria for transitional pass-through payment is a very positive development for severe asthmatics and the pulmonary physician community," BSX endoscopy division president David Pierce said in prepared remarks."It supports what we have confirmed through our clinical trials:  bronchial thermoplasty offers a new advancement in the treatment of patients with severe asthma who are not well controlled despite taking recommended doses of asthma medications.  This decision also sets an important precedent for health care payers throughout the United States."